Participant flow

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer · Source last updated 2025-03-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Margetuximab 15 mg/kg administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.

   id

   FG000

   title

   Margetuximab Plus Chemotherapy

2. description

   Trastuzumab administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.

   id

   FG001

   title

   Trastuzumab Plus Chemotherapy

3. description

   Margetuximab with or without chemotherapy administered as a 120 minute first infusion in Cycle 1 followed by 60-minute or 30-minute infusion in Cycle 2.

   id

   FG002

   title

   Margetuximab Infusion Substudy

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         9

      3. group Id

         FG002

         num Subjects

         2

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         3

      3. group Id

         FG002

         num Subjects

         0

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         16

      3. group Id

         FG002

         num Subjects

         5

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         4

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         1

      type

      Lost to Follow-up

   6. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      type

      study treatment delay

   7. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      type

      change in chemotherapy

   8. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         4

      3. group Id

         FG002

         num Subjects

         0

      type

      never treated

   9. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         1

      type

      Other

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         266

      2. group Id

         FG001

         num Subjects

         270

      3. group Id

         FG002

         num Subjects

         88

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         266

      2. group Id

         FG001

         num Subjects

         270

      3. group Id

         FG002

         num Subjects

         88

      type

      Intent-to-treat (ITT) Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         264

      2. group Id

         FG001

         num Subjects

         266

      3. group Id

         FG002

         num Subjects

         88

      type

      Safety Population

   4. achievements

      1. group Id

         FG000

         num Subjects

         230

      2. group Id

         FG001

         num Subjects

         230

      3. group Id

         FG002

         num Subjects

         75

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         36

      2. group Id

         FG001

         num Subjects

         40

      3. group Id

         FG002

         num Subjects

         13

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice